store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vevorisertib trihydrochloride(ARQ 751 trihydrochloride) 是一种具有选择性和有效性的 pan-AKT 和 AKT1-E17K 突变抑制剂,抑制 AKT1 、AKT2 和 AKT3 。 Vevorisertib trihydrochloride 可用于研究肝癌和晚期实体瘤。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 469 | 现货 | ||
5 mg | ¥ 1,130 | 现货 | ||
10 mg | ¥ 1,690 | 现货 | ||
25 mg | ¥ 2,880 | 现货 | ||
50 mg | ¥ 3,970 | 现货 | ||
100 mg | ¥ 5,470 | 现货 |
产品描述 | Vevorisertib trihydrochloride (ARQ 751 trihydrochloride) is a selective and potent inhibitor of pan-AKT and AKT1-E17K mutations, inhibiting AKT1, AKT2 and AKT3. Vevorisertib trihydrochloride is used in the study of hepatocellular carcinoma and advanced solid tumours. |
靶点活性 | Akt1 (E17K):8.6 nM (Kd), Akt1:1.2 nM (Kd), Akt1:0.55 nM, Akt3:1.31 nM, Akt2:0.81 nM |
体外活性 | Vevorisertib trihydrochloride (0、12、33、111、333、1000 nM,2小时)抑制AKT1-E17K的磷酸化[2]。无论是否存在生长因子,Vevorisertib trihydrochloride (1 μM,2小时;NIH 3T3细胞转染pcDNAAKT-WT-GFP或pcDNA-E17K-GFP)均能抑制AKT-WT和AKT1-E17K的质膜转移[2]。Vevorisertib trihydrochloride (5 μM)表现出对全长AKT1 57%的抑制作用[1]。Vevorisertib trihydrochloride (0、0.012、0.037、0.11、0.33、1 μM;2小时)对mTORC1及AKT直接底物(包括PRAS40、GSK3β、FOXO、BAD及AS160)显示出剂量依赖性效应,适用于癌细胞系[2]。Vevorisertib trihydrochloride 对食管癌、乳腺癌和头颈癌细胞具有抗增殖作用(GI 50 < 1 μM)[1]。在PIK3CA突变细胞系中,Vevorisertib trihydrochloride 展现强烈的抗增殖活性[2]。Vevorisertib trihydrochloride (MK-4440)/伊马替尼美西酸盐(IM)组合能促进胃肠间质瘤(GIST)细胞周期阻滞,并增加细胞死亡率[1]。再次强调,在PIK3CA突变细胞系中,Vevorisertib trihydrochloride 显著抑制细胞增殖[2]:乳腺癌细胞系的GI 50 (nM)数据表明,与PIK3CA、ER、PR、HER2状态相关的各细胞系均对Vevorisertib trihydrochloride 敏感。Western Blot分析[1][2]显示,Vevorisertib trihydrochloride 能够抑制AKT1-E17K的磷酸化,并对mTORC1及AKT直接底物表现出剂量依赖性抑制效应,展现了其对各类癌细胞系具有广泛的抑制作用。 |
体内活性 | Vevorisertib trihydrochloride (25, 50 and 75 mg/kg; p.o.; 5 days dosing followed by a 4 day dosing holiday for 20 days) shows potent tumor growth inhibition of 68, 78 and 98%, respectively [2] . Vevorisertib trihydrochloride (5, 10, 20, 40, 80, and 120 mg/kg; p.o. daily for ten days) shows tumor growth inhibition of 29, 33, 50, 73, 83, and 92%, respectively [2] . Vevorisertib trihydrochloride reachs C max plasma concentrations of ≥2 μM [2] . Vevorisertib trihydrochloride is generally well-tolerated at dose levels up to 120 mg/kg [2] . Vevorisertib trihydrochloride (MK-4440)/IM combination shows superior efficacy in an IM-sensitive preclinical model of GIST compared with either single agent [1] . Animal Model: Endometrial PDX mouse xenograft models (AKT1-E17K mutation tumor fragments subcutaneously implanted in athymic nude mice; tumor volume of approximately 200 mm 3 ) [2] Dosage: 25, 50 and 75 mg/kg Administration: p.o.; 5 days dosing followed by a 4 day dosing holiday for 20 days Result: Showed potent tumor growth inhibition of 68, 78 and 98%, respectively. Animal Model: AN3CA mouse xenograft models (female NCr nu/nu mice with 250 mm 3 tumors size) [2] Dosage: 5, 10, 20, 40, 80, and 120 mg/kg Administration: p.o.; daily for ten days Result: Showed tumor growth inhibition of 29, 33, 50, 73, 83, and 92%, respectively. |
别名 | ARQ 751 trihydrochloride |
分子量 | 696.12 |
分子式 | C35H41Cl3N8O |
CAS No. | 1416775-08-0 |
store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 20 mg/mL (28.73 mM)
DMSO: 100 mg/mL (143.66 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 1.4365 mL | 7.1827 mL | 14.3653 mL | 35.9133 mL |
5 mM | 0.2873 mL | 1.4365 mL | 2.8731 mL | 7.1827 mL | |
10 mM | 0.1437 mL | 0.7183 mL | 1.4365 mL | 3.5913 mL | |
20 mM | 0.0718 mL | 0.3591 mL | 0.7183 mL | 1.7957 mL | |
DMSO | 50 mM | 0.0287 mL | 0.1437 mL | 0.2873 mL | 0.7183 mL |
100 mM | 0.0144 mL | 0.0718 mL | 0.1437 mL | 0.3591 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Vevorisertib trihydrochloride 1416775-08-0 Cytoskeletal Signaling PI3K/Akt/mTOR signaling Akt ARQ-751 Trihydrochloride ARQ751 Trihydrochloride ARQ751 ARQ-751 ARQ 751 Vevorisertib ARQ 751 trihydrochloride Inhibitor inhibitor inhibit